FCRL5 and neoplasm: In the NCI-H929-luc subcutaneous model (Fig. 6e), both FCRL5-targeted CAR-T cell treatments initially attenuated tumor progression; however, FCRL5 CAR-T/IL-15 demonstrated enhanced therapeutic sustainability, with mice experiencing prolonged survival until the conclusion of the study (Fig. 6f, g).